Skip to Content
Merck
  • Metabolic priming by multiple enzyme systems supports glycolysis, HIF1α stabilisation, and human cancer cell survival in early hypoxia.

Metabolic priming by multiple enzyme systems supports glycolysis, HIF1α stabilisation, and human cancer cell survival in early hypoxia.

The EMBO journal (2024-03-15)
Fiona Grimm, Agustín Asuaje, Aakriti Jain, Mariana Silva Dos Santos, Jens Kleinjung, Patrícia M Nunes, Stefanie Gehrig, Louise Fets, Salihanur Darici, James I MacRae, Dimitrios Anastasiou
ABSTRACT

Adaptation to chronic hypoxia occurs through changes in protein expression, which are controlled by hypoxia-inducible factor 1α (HIF1α) and are necessary for cancer cell survival. However, the mechanisms that enable cancer cells to adapt in early hypoxia, before the HIF1α-mediated transcription programme is fully established, remain poorly understood. Here we show in human breast cancer cells, that within 3 h of hypoxia exposure, glycolytic flux increases in a HIF1α-independent manner but is limited by NAD+ availability. Glycolytic ATP maintenance and cell survival in early hypoxia rely on reserve lactate dehydrogenase A capacity as well as the activity of glutamate-oxoglutarate transaminase 1 (GOT1), an enzyme that fuels malate dehydrogenase 1 (MDH1)-derived NAD+. In addition, GOT1 maintains low α-ketoglutarate levels, thereby limiting prolyl hydroxylase activity to promote HIF1α stabilisation in early hypoxia and enable robust HIF1α target gene expression in later hypoxia. Our findings reveal that, in normoxia, multiple enzyme systems maintain cells in a primed state ready to support increased glycolysis and HIF1α stabilisation upon oxygen limitation, until other adaptive processes that require more time are fully established.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-GLUT-1 Antibody, CT, from rabbit, purified by affinity chromatography
Sigma-Aldrich
Goat Anti-Rabbit IgG Antibody, Peroxidase Conjugated, 1 mg/mL (after reconstitution), Chemicon®
Sigma-Aldrich
Monoclonal Anti-β-Actin antibody produced in mouse, clone AC-74, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
scyllo-Inositol, ≥98%
Sigma-Aldrich
Puromycin dihydrochloride from Streptomyces alboniger, ≥98% (HPLC), powder
Sigma-Aldrich
Oligomycin from Streptomyces diastatochromogenes, ≥90% total oligomycins basis (HPLC)
Sigma-Aldrich
Monoclonal Anti-α-Tubulin antibody produced in mouse, clone DM1A, ascites fluid
Sigma-Aldrich
Antimycin A from Streptomyces sp.
Sigma-Aldrich
MG-132, ≥95% by HPLC, Potent, reversible, and cell-permeable proteasome inhibitor (Ki = 4 nM).
Sigma-Aldrich
Goat Anti-Mouse IgG Antibody, Fc, HRP conjugate, 0.8 mg/mL, Chemicon®
Sigma-Aldrich
Glucose Transporter Inhibitor IV, WZB117, The Glucose Transporter Inhibitor IV, WZB117 controls the biological activity of Glucose Transporter.